We view her role as a sign of our commitment and dedication to supplying our customers with patent protected, clinically substantiated, and innovative ingredients.
(PRWEB) April 14, 2016
Nutrition 21, LLC, a leading developer and marketer of efficacious, high-value, patented nutritional products whose health benefits are substantiated with clinical research, announced today that Sara O’Brien has joined as General Counsel of JDS Therapeutics, and its wholly owned subsidiary Nutrition 21.
Ms. O’Brien joins Nutrition 21 after working in the Intellectual Property departments of Willkie Farr & Gallagher and Ropes & Gray, where she most recently specialized in patent litigation. Sara’s private practice included extensive intellectual property work in the pharmaceutical and biotechnology sectors as well as intellectual property portfolio management. Her litigation experience encompasses a range of technologies, including biologics, pharmaceuticals, computer software, and other technologies. Her practice also encompassed intellectual property-based commercial transaction work such as complex contracts, licensing and supply agreements and bankruptcies.
Michael Satow, CEO and President of Nutrition 21 said, “Sara’s intellectual property experience and industry knowledge make her a prime addition to the Nutrition 21 team. We view her role as a sign of our commitment and dedication to supplying our customers with patent protected, clinically substantiated, and innovative ingredients. We are confident that Sara will play a vital role in our business.”
Sara received her J.D. with Honors from the University of Connecticut and a B.S. in Biology and Psychology with High Honors from Carnegie Mellon University.
About Nutrition 21, LLC
Nutrition 21, a wholly owned subsidiary of JDS Therapeutics, is a leader in the nutritional supplement industry. With many years of biotechnology and pharmaceutical experience, the Company’s scientific platform has created unique, patented products that are safe and clinically effective. Rigorous preclinical and clinical trials are a key part of its product development strategy to ensure product safety and consumer trust. Nutrition 21 currently holds over 100 domestic and international issued and pending patents for products. Many support unique claims associated with, among others, glucose metabolism, weight management, cognition, and sports nutrition.
The Company is a developer and marketer of efficacious, high-value, clinically substantiated ingredients for dietary supplements, medical foods and beverages. Nutrition 21’s branded ingredients include: new Velositol™ amylopectin chromium complex, clinically shown to double the effects of whey protein -- significantly increasing muscle protein synthesis, the key to muscle growth; Chromax® chromium picolinate, with clinically substantiated benefits for glucose metabolism, weight management, and brain health; Nitrosigine® bonded arginine silicate, is clinically shown to significantly boost nitric oxide levels supporting mental acuity/focus and sports nutrition. Nitric oxide is a key factor in promoting the relaxation of smooth muscle in blood vessels, increasing blood flow to working muscles.
For more information, please visit: http://www.Nutrition21.com
Nutrition 21, LLC
President & CEO